Transcription factor 7-like 2 polymorphism and colon cancer

Martha L. Slattery, Aaron R. Folsom, Roger Wolff, Jenifer Herrick, Bette J. Caan, John D. Potter

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Abstract

Polymorphisms of the transcription factor 7-like 2 (TCF7L2) gene have been associated with insulin sensitivity andd iabetes, andthe TCF7L2 gene is involvedin the Wnt/β-catenin signaling pathway, all factors thought to be important in the etiology of colon cancer. In this confirmatory study, we evaluated the rs7903146 TCF7L2 polymorphism with colon cancer using previously collectedd ata on 1,578 cases and1,966 controls. We did not observe a statistically significant association between the rs7903146 polymorphisms and risk of colon cancer [odds ratio (OR), 1.12; 95% confidence interval (95% CI), 0.98-1.28] when evaluating the total population. We did, however, observe a statistically significant interaction between the rs7903146 TCF7L2 polymorphism and recent use of aspirin/nonsteroidal anti-inflammatory drugs (NSAID; P = 0.001). Increased colon cancer risk associated with the T allele was restricted to those without recent use of aspirin/NSAIDs (OR, 1.65; 95% CI, 1.35-2.02, relative to recent aspirin users, i.e., use of aspirin/NSAIDS within the 2 years before diagnosis, with the CC genotype). Among individuals who reportedrecent use of aspirin/NSAIDs, the T allele reduced risk of colon cancer (OR, 0.78; 95% CI, 0.62-0.98) in a dose-response fashion (P for linear trend across genotypes = 0.03). These data suggest that colon cancer risk associated with the rs7903146 TCF7L2 polymorphism is modified by use of aspirin/NSAIDs.

Original languageEnglish (US)
Pages (from-to)978-982
Number of pages5
JournalCancer Epidemiology Biomarkers and Prevention
Volume17
Issue number4
DOIs
StatePublished - Apr 2008

Fingerprint

Dive into the research topics of 'Transcription factor 7-like 2 polymorphism and colon cancer'. Together they form a unique fingerprint.

Cite this